Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

Like other prescription medicines, Viagra and its generic form, sildenafil, work best when you take them under the right ...

Hims offers convenient and affordable access to treatments and products tailored for men's health needs. But how much does it ...

If you’re on the fence about investing in Patterson Companies, Inc., Hims & Hers Health or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before ...

Financial giants have made a conspicuous bearish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health HIMS revealed 9 unusual trades. Delving into the details ...

Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $42.00. Discover the ...

Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss ...

Hims & Hers Health (NYSE:HIMS) is down 7% in early morning trading after the U.S. FDA determined that there is no shortage of Eli Lilly's (LLY) GLP-1 medication tirzepatide, the active ingredient ...

The FDA announced that the tirzepatide injection shortage is resolved. Hims & Hers Health, Inc.'s stock fell 6.90%, reflecting market concerns over regulatory updates and supply chain stability.

Investing.com -- Shares of Hims & Hers Health, Inc. (NYSE: HIMS) fell sharply by 15% after the U.S. Food and Drug Administration (FDA) announced the resolution of the tirzepatide injection shortage.